Loading...
Primary myelofibrosis and myelofibrosis evolving from polycythemia vera or essential thrombocytosis are characterized by Janus kinase (JAK) mutations that activate JAK signaling pathways; treatment with available JAK inhibitors can improve splenic volume and symptoms but has no impact on or may worsen anemia. Momelotinib is an investigational oral JAK inhibitor that also inhibits activin A receptor type 1, a regulator of iron metabolism. Investigators conducted an industry-sponsored, multicenter, double-blind phase 3 trial (MOMENTUM) comparing momelotinib to danazol, an androgen with erythropoietic stimulating activity.
A total of 195 patients with myelofibrosis and anemia who previously received treatment with an approved JAK inhibitor were…